MALVERN, Pa. (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (“RBC”) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot(SM) drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more.
RBC’s HotSpot(SM) technology is an ultra-low volume tritium-based assay platform that provides gold-standard methyltransferase inhibition data.
The technology is offered as a screening service, allowing clients to avoid operational issues related to dealing with radioisotope management, and quickly find productive lead candidates.
RBC Chief Technology Officer Haiching Ma said, “Epigenetic mechanisms are increasingly recognized as fundamental to several cancers and many other diseases. Up until now, there has been no cost-effective way to do large-scale methyltransferase screening and profiling. We hope that RBC’s ability to fill this unmet need will speed the discovery of new drugs in this area.”
Based in Malvern, PA, RBC specializes in providing high quality biochemical enzyme assay data, using ultra-low volumes and proprietary methods. RBC has provided its services to over 190 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.
RBC’s Kinase HotSpot platform is a widely used service for providing high quality low-cost kinase screening data worldwide. The company also provides HDAC, protease, and other screening services, as well as custom assay development and partnerships.
For more information, visit: www.reactionbiology.com .